MapLight Reports $351M Cash, Extends Runway Through 2028 After Positive ZEPHYR Data
MPLT sits 30% above its 52-week low of $9.1.
Summary
MapLight reported Q2 2026 results with $351.3 million in cash, which combined with the recent $150 million private placement extends runway through 2028. The company reiterated positive Phase 2 ZEPHYR data for ML-007C-MA in schizophrenia and plans an End-of-Phase 2 FDA meeting to advance into Phase 3 ZEPHYR-2. Enrollment continues in the Phase 2 VISTA trial for Alzheimer's disease psychosis, with topline results expected in the second half of 2027. For ML-004 in autism, the company will evaluate strategic collaborations or funding alternatives after FDA discussions. This follows the CFO separation in June and the mixed ZEPHYR data reported in July, but the cash position and clear development path are the key takeaways.
At the time of this announcement, MPLT was trading at $11.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $493.5M. The 52-week trading range was $9.10 to $40.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.